← Leaderboards
Yibing Qyang
Yale University
$11,472,161
Attributed
$11,472,161
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,472,161 · 7
By mechanism
R01$10,983,206 · 6
K02$488,955 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Michael P Snyder$209,065,560
- Yujun Cai$1,264,833
- Jay D Humphrey$27,724,941
- Luke Daniel Batty$125,856
- Christopher W Anderson$135,060
Others in their field
Top investigators on “Somatic Cell”
- Dennis R. Burton · Scripps Research Institute$261,087,746
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$64,910,059
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Linda M Brzustowicz · Rutgers The St Univ Of Nj New Brunswick$50,800,152
- Rudolf Jaenisch · Whitehead Institute For Biomedical Res$32,217,463
- Supriya Menezes · The Emmes Company, Llc$25,277,032
Research focus
Somatic CellInduced Pluripotent Stem CellCellsIn VitroRattusGenesImplantScaffoldIn VivoMechanicsBioreactorsAutologousProductionFutureSmooth Muscle MyocytesIn Vivo ModelBaseCell TypeSourcePropertyStem CellsEndothelial CellsImplantationOperative Surgical Procedures
Grant awards (32)
Readily Available Biological Conduits to Treat Single Ventricle Defects$575,239
R01 · FY2025 · HL · contact PI
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction$418,750
R01 · FY2025 · HL · contact PI
Readily Available Biological Conduits to Treat Single Ventricle Defects$571,889
R01 · FY2024 · HL · contact PI
Development of HLA engineered universal vascular grafts from human iPSCs$418,750
R01 · FY2024 · HL · contact PI
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction$418,750
R01 · FY2024 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$664,327
R01 · FY2023 · HL · contact PI
Development of HLA engineered universal vascular grafts from human iPSCs$418,750
R01 · FY2023 · HL · contact PI
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction$418,750
R01 · FY2023 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$11,422
R01 · FY2023 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$664,327
R01 · FY2022 · HL · contact PI
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction$418,750
R01 · FY2022 · HL · contact PI
Development of HLA engineered universal vascular grafts from human iPSCs$418,750
R01 · FY2022 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$63,808
R01 · FY2022 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$11,035
R01 · FY2022 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$664,327
R01 · FY2021 · HL · contact PI
Development of HLA engineered universal vascular grafts from human iPSCs$418,750
R01 · FY2021 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$61,871
R01 · FY2021 · HL · contact PI
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care$623,260
R01 · FY2020 · HL · contact PI
Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy$418,750
R01 · FY2019 · HL · contact PI
Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy$418,750
R01 · FY2018 · HL · contact PI
Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy$418,750
R01 · FY2017 · HL · contact PI
Human tissue-engineered blood vessels using induced pluripotent stem cells$416,250
R01 · FY2017 · HL · contact PI
Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy$418,750
R01 · FY2016 · HL · contact PI
Human tissue-engineered blood vessels using induced pluripotent stem cells$416,250
R01 · FY2016 · HL · contact PI
Human tissue-engineered blood vessels using induced pluripotent stem cells$410,006
R01 · FY2015 · HL · contact PI
Human tissue-engineered blood vessels using induced pluripotent stem cells$407,925
R01 · FY2014 · HL · contact PI
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells$98,364
K02 · FY2014 · HL · contact PI
Human tissue-engineered blood vessels using induced pluripotent stem cells$396,270
R01 · FY2013 · HL · contact PI
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells$98,364
K02 · FY2013 · HL · contact PI
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem Cells$98,364
K02 · FY2012 · HL · contact PI
Derivation and Functional Characterization of Heart Cells from Human Embryonic an$98,364
K02 · FY2011 · HL · contact PI
Derivation and Functional Characterization of Heart Cells from Human Embryonic an$95,499
K02 · FY2010 · HL · contact PI